T2* in Transfusion Dependant Anemia, MI, LVF, Normal Patients
NCT00520559 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 652
Last updated 2024-02-14
Summary
The purpose of this study is to provide accurate prognostic data linking cardiac complications to myocardial T2\* values (A measure of iron levels in the heart using MRI)in patients predisposed to heart iron overload.
Conditions
Sponsors & Collaborators
-
Imperial College London
lead OTHER
Principal Investigators
-
Dudley Pennell, MA, MD · Imperial College London
Eligibility
- Min Age
- 18 Years
- Max Age
- 77 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2007-01-31
- Completion
- 2007-08-31
More Related Trials
-
Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron Overload
NCT00673608 ·Status: COMPLETED ·Phase: PHASE4
-
Atrial Fibrillation in Beta-Thalassemia
NCT05508932 ·Status: RECRUITING
-
IRONHEART: Intravenous Iron in Non-ischaemic Heart Failure
NCT06542822 ·Status: RECRUITING
-
Evaluation of the Free α-hemoglobin Pool in the Red Blood Cells : Prognostic Marker and Severity Index in Thalassemic Syndromes
NCT02855957 ·Status: COMPLETED ·Phase: NA
-
Evaluating People With Thalassemia: The Thalassemia Longitudinal Cohort (TLC) Study
NCT00661804 ·Status: COMPLETED
-
Iron Status in BTM With Blood Transfusion
NCT04947540 ·Status: UNKNOWN
-
Assessment of Pain in People With Thalassemia
NCT00872339 ·Status: COMPLETED
-
High-Tc Susceptometer to Monitor Transfusional Iron Overload
NCT01241357 ·Status: COMPLETED
-
Deferasirox BID (Twice a Day) in Transfusion Dependent Thalassemia Patients With Inadequate Response to High Doses
NCT01948817 ·Status: WITHDRAWN ·Phase: PHASE2
-
Deferoxamine for the Treatment of Hemochromatosis
NCT00001203 ·Status: COMPLETED
-
Iron Mediated Vascular Disease in Sickle Cell Anemia Patients
NCT01239901 ·Status: COMPLETED
-
Effect of Deferasirox on Patients With Cardiac MRI T2* < 20 Msec
NCT00879242 ·Status: COMPLETED ·Phase: PHASE2
-
Statistical Basis for Hemochromatosis Screening
NCT00005559 ·Status: COMPLETED
-
Transferrin Saturation and Asthenia in Hemochromatosis
NCT03356548 ·Status: COMPLETED
-
Efficacy and Safety of Efficacy and Safety of Continued Iron Chelation Therapy In Poly-transfused Thalassemia Patients With Low Serum Ferritin (< 500 ng/ml)
NCT01996683 ·Status: UNKNOWN ·Phase: NA
-
Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload
NCT00564941 ·Status: COMPLETED ·Phase: PHASE4
-
Cardiac Function in Patients With Hereditary Hemochromatosis
NCT00068159 ·Status: COMPLETED
-
Detection of β Thalassemia Carriers by Red Cell Parameters Obtained From the H2 Automatic Counter
NCT00481221 ·Status: UNKNOWN
-
Blood Transfusions in Thalassemia Patients, Complications and Adverse Effects
NCT00971880 ·Status: COMPLETED
-
MRI Evaluation of Iron Overload in the Heart, Liver and Pancreas in Patients Receiving Multiple Blood Transfusions.
NCT00629291 ·Status: COMPLETED
-
Predisposing Factors for Liver Diseases in Patients With Chronic Hemolytic Anemia
NCT06743854 ·Status: NOT_YET_RECRUITING
-
Detection Of β-thalassemia Carriers In Assiut
NCT03822585 ·Status: UNKNOWN ·Phase: NA
-
Phase I Study to Examine the Effect of Deferasirox on Renal Hemodynamics in β-thalassemia Patients With Transfusional Iron Overload
NCT00560820 ·Status: COMPLETED ·Phase: PHASE1
-
Assessment of Pain in People With Thalassemia Who Are Treated With Regular Blood Transfusions
NCT00872833 ·Status: COMPLETED
-
Intravenous Iron in paTients With Heart failURe and Reduced Ejection fracTion (HFREF) pLus Iron dEficiency
NCT03079518 ·Status: COMPLETED ·Phase: PHASE2